Intensive red blood cell transfusions and risk of alloimmunization

Transfusion. 2014 Feb;54(2):278-84. doi: 10.1111/trf.12312. Epub 2013 Jun 19.

Abstract

Background: Exposure to allogenic red blood cells (RBCs) may lead to formation of antibodies against nonself-antigens in transfused patients. While alloimmunization rates are known to increase with the number of transfusions, the transfusion course in patients can vary from receiving multiple units during a single transfusion event or getting them dispersed over a long(er) period. In this study we compared the immunization risk between different transfusion intensities.

Study design and methods: An incident new-user cohort study was conducted among consecutive transfused patients at two university medical centers. All patients who received their first RBC transfusion within the study period from January 2005 to December 2011 were eligible. Intensive transfusions were defined as at least 5, at least 10, and at least 20 RBC units within 48 hours. Alloimmunization hazard ratios (HRs), comparing patients receiving intensive transfusions to patients never receiving intensive transfusions, were estimated.

Results: The study cohort was composed of 5812 patients who had received a median of 7 (interquartile range, 4-12) units. RBC alloantibodies were formed by 156 patients. The adjusted Cox regression HRs for alloimmunization, with number of units as the time covariate and adjusted for patient age, sex, and follow-up time after first transfusion, ranged from 0.8 to 1.2 (95% confidence interval, 0.4-2.6).

Conclusion: The occurrence of RBC alloimmunization in patients receiving intensive transfusions did not differ significantly from patients receiving nonintensive transfusions.

MeSH terms

  • Adult
  • Aged
  • Blood Group Incompatibility / epidemiology*
  • Blood Group Incompatibility / immunology
  • Cohort Studies
  • Erythrocyte Transfusion / adverse effects*
  • Erythrocyte Transfusion / statistics & numerical data*
  • Female
  • Follow-Up Studies
  • Humans
  • Incidence
  • Isoantibodies / blood*
  • Male
  • Middle Aged
  • Proportional Hazards Models
  • Risk Factors
  • Young Adult

Substances

  • Isoantibodies